JP2013518090A5 - - Google Patents

Download PDF

Info

Publication number
JP2013518090A5
JP2013518090A5 JP2012550512A JP2012550512A JP2013518090A5 JP 2013518090 A5 JP2013518090 A5 JP 2013518090A5 JP 2012550512 A JP2012550512 A JP 2012550512A JP 2012550512 A JP2012550512 A JP 2012550512A JP 2013518090 A5 JP2013518090 A5 JP 2013518090A5
Authority
JP
Japan
Prior art keywords
xaa
pyy
group
analog
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012550512A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013518090A (ja
Filing date
Publication date
Priority claimed from GBGB1001333.2A external-priority patent/GB201001333D0/en
Application filed filed Critical
Publication of JP2013518090A publication Critical patent/JP2013518090A/ja
Publication of JP2013518090A5 publication Critical patent/JP2013518090A5/ja
Pending legal-status Critical Current

Links

JP2012550512A 2010-01-27 2011-01-27 新規化合物及び摂食行動に対するそれらの効果 Pending JP2013518090A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1001333.2A GB201001333D0 (en) 2010-01-27 2010-01-27 Novel compounds and their effects on feeding behaviour
GB1001333.2 2010-01-27
PCT/GB2011/000110 WO2011092473A1 (en) 2010-01-27 2011-01-27 Novel compounds and their effects on feeding behaviour

Publications (2)

Publication Number Publication Date
JP2013518090A JP2013518090A (ja) 2013-05-20
JP2013518090A5 true JP2013518090A5 (OSRAM) 2014-03-13

Family

ID=42084054

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012550512A Pending JP2013518090A (ja) 2010-01-27 2011-01-27 新規化合物及び摂食行動に対するそれらの効果

Country Status (13)

Country Link
US (1) US9018160B2 (OSRAM)
EP (1) EP2528942B1 (OSRAM)
JP (1) JP2013518090A (OSRAM)
KR (1) KR20120127610A (OSRAM)
CN (1) CN102741278A (OSRAM)
AU (1) AU2011210165B2 (OSRAM)
BR (1) BR112012018703A2 (OSRAM)
CA (1) CA2788013A1 (OSRAM)
GB (1) GB201001333D0 (OSRAM)
MX (1) MX2012008792A (OSRAM)
RU (1) RU2012136530A (OSRAM)
SG (1) SG182578A1 (OSRAM)
WO (1) WO2011092473A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
SG11201508469YA (en) * 2013-05-02 2015-11-27 Glaxosmithkline Ip Dev Ltd Therapeutic peptides
WO2015177573A1 (en) * 2014-05-23 2015-11-26 Imperial Innovations Limited Peptide yy (pyy) analogues
WO2015177572A1 (en) 2014-05-23 2015-11-26 Imperial Innovations Limited Peptide yy (pyy) analogues
US20170040801A1 (en) * 2015-08-04 2017-02-09 Goal Zero Llc Portable solar panel system electrical control
JP7117779B2 (ja) 2015-12-16 2022-08-15 ダイエット4ライフ・アンパルトセルスカブ 食品ペプチド
GB201720188D0 (en) 2017-12-04 2018-01-17 Imperial Innovations Ltd Analogues of PYY
EP3743092A4 (en) 2018-01-23 2021-10-20 Gila Therapeutics, Inc. PHARMACEUTICAL PEPTIDE-YY FORMULATIONS, COMPOSITIONS, AND PROCEDURES
GB2573145A (en) * 2018-04-26 2019-10-30 Univ Ulster Peptides for metabolic disease
GB201908426D0 (en) 2019-06-12 2019-07-24 Imp College Innovations Ltd Appetite suppressing compounds
US11739134B2 (en) 2020-04-17 2023-08-29 Intarcia Therapeutics, Inc. Long acting peptide tyrosine tyrosine (PYY) analogs and methods of use
CN114075265B (zh) * 2020-08-13 2025-08-29 珠海市丽珠微球科技有限公司 一种多肽酪氨酸酪氨酸类似物以及包含其的缓释制剂

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CA1257199A (en) 1986-05-20 1989-07-11 Paul Y. Wang Preparation containing bioactive macromolecular substance for multi-months release in vivo
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
ATE180510T1 (de) 1991-11-06 1999-06-15 Garvan Inst Med Res Humaner neuropeptid y-y1 rezeptor
AU7531094A (en) 1993-08-24 1995-03-21 Novo Nordisk A/S Protracted glp-1
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US5962270A (en) 1996-02-06 1999-10-05 Bionebraska, Inc. Recombinant preparation of calcitonin fragments and use thereof in the preparation of calcitonin and related analogs
US6355478B1 (en) 1996-06-17 2002-03-12 Eli Lilly And Company Rhesus monkey neuropeptide Y Y2 receptor
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
FR2774674B1 (fr) 1998-02-10 2000-03-24 Atochem Elf Sa Procede de preparation d'une solution aqueuse de peroxyde d'hydrogene directement a partir d'hydrogene et d'oxygene et dispositif permettant sa mise en oeuvre
US5993414A (en) 1998-04-23 1999-11-30 Medtronic, Inc. Implantable device
US6436091B1 (en) 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
US6420352B1 (en) 2000-07-19 2002-07-16 W. Roy Knowles Hair loss prevention
ES2320979T3 (es) 2001-09-24 2009-06-01 Imperial Innovations Limited Pyy-36 para la reduccion o prevencion de la obesidad.
US7186692B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
EP1789440A4 (en) * 2004-02-11 2008-03-12 Amylin Pharmaceuticals Inc REASONS FOR THE FAMILY OF PANCREATIC POLYPEPTIDES AND POLYPEPTIDES CONTAINING THEM
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EP2233497A3 (en) 2004-02-11 2011-01-12 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
IN2012DN03921A (OSRAM) 2004-02-11 2015-09-04 Amylin Pharmaceuticals Inc
WO2005089790A2 (en) 2004-03-17 2005-09-29 7Tm Pharma A/S Y2/y4 selective receptor agonists for therapeutic interventions
MXPA06010345A (es) 2004-03-17 2007-06-19 7Tm Pharma As Agonistas de receptor selectivo de y4 para intervenciones terapeuticas.
US20090186811A1 (en) 2004-03-17 2009-07-23 Thue Schwartz Y2 Selective Receptor Agonists for Therapeutic Interventions
WO2005089789A2 (en) * 2004-03-17 2005-09-29 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions
BRPI0516574A (pt) 2004-10-08 2008-09-16 Amylin Pharmaceuticals Inc análogos do polipeptìdeo-6 da famìlia amilina (afp-6) e métodos para preparar e usar os mesmos
JP5743371B2 (ja) * 2004-12-13 2015-07-01 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 膵臓ポリペプチドファミリーモチーフ、ポリペプチドおよびこれらを含む方法
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
JP4629488B2 (ja) 2005-04-28 2011-02-09 本田技研工業株式会社 プラントを制御する制御装置
US20090054326A1 (en) 2005-07-11 2009-02-26 Nastech Pharmaceutical Company Inc. Formulations for enhanced mucosal delivery of pyy
AU2006279680B2 (en) 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
KR101399178B1 (ko) * 2005-08-11 2014-06-18 아스트라제네카 파마수티컬스 엘피 선별가능한 특성을 갖는 하이브리드 폴리펩티드
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
WO2009007714A2 (en) 2007-07-09 2009-01-15 Imperial Innovations Limited Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour
EP2195034A2 (en) * 2007-09-27 2010-06-16 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
JP2011520847A (ja) * 2008-05-16 2011-07-21 ノボ・ノルデイスク・エー/エス 遅効型y2及び/又はy4レセプターアゴニスト

Similar Documents

Publication Publication Date Title
JP2013518090A5 (OSRAM)
RU2012136530A (ru) Новые соединения, влияющие на пищевое поведение
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
AU2018213964B2 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
ES2976562T3 (es) Derivado del glucagón
RU2485135C2 (ru) Соединения оксинтомодулина (варианты), фармацевтическая композиция на их основе, способы лечения и профилактики ожирения и сопутствующих заболеваний (варианты) и лекарственное средство (варианты)
KR101794781B1 (ko) 펩타이드계 glp-2 작용제
JP6266811B2 (ja) 血管新生病の免疫療法
CA2965560A1 (en) Compositions and peptides having dual glp-1r and glp-2r agonist activity
HUE029798T2 (en) Methods of administering hypoglycemic agents
CN101203531A (zh) 修饰的pyy(3-36)多肽及它们对进食行为的影响
TW200520770A (en) Glp-1 pharmaceutical compositions
KR101661332B1 (ko) 글루카곤 유사 펩타이드-1 수용체 항진제를 포함하는 근감소증 치료용 약학 조성물
CA3073011C (en) Acylated oxyntomodulin peptide analog
CA3222051A1 (en) Polypeptide derivative having effect of dual targeted activation of glp-1r and gipr, preparation method therefor, and use thereof
JP2025166052A (ja) 肥満の治療における使用のためのil-4由来ペプチド
RU2297238C2 (ru) Аддитивные цитопротекторные эффекты двух биоактивных областей гормона про-опиомеланокортина
JP2009528303A5 (OSRAM)
WO2024209050A1 (en) Gip activity modulators and orthostatic intolerance
JP2021525261A (ja) 代謝疾患の治療におけるigfbp−2のヘパリン結合ドメイン
WO2019103660A1 (en) Method of multiple sclerosis treatment (variants)
KR20250095833A (ko) 에페글레나타이드를 유효성분으로 포함하는 약학 조성물 및 이의 투여 요법
KR20180027924A (ko) 글루카곤 유사 펩타이드-1(glp-1), glp-1 유래 펩타이드, 또는 glp-1 분해 억제제를 포함하는 근감소증 또는 근위축증 치료용 약학 조성물
HK40010066B (en) Glucagon derivative
TH2101002460A (th) โปรตีนไทโรซีน-ไทโรซีน อะนาล็อกและวิธีการใช้สิ่งเดียวกัน